Cara Therapeutics reported $-30815000 in EBITDA for its second fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Ebitda Change
Acadia Pharmaceuticals ACAD:US $ -42.78M 23.1M
Acelrx Pharmaceuticals ACRX:US $ -9.1M 0.11M
Aerie Pharmaceuticals AERI:US $ -29.84M 2.88M
Antares Pharma ATRS:US $ 7.71M 1.42M
Arena Pharmaceuticals ARNA:US $ -143.42M 12.4M
Cara Therapeutics CARA:US $ -30815000 7.32M
Endo International Ordinary Shares ENDP:US $ 314.75M 18.87M
Halozyme Therapeutics HALO:US $ 93.85M 42.37M
Horizon Pharma HZNP:US $ 305.69M 324.32M
JAZZ PHA JAZZ:US $ 77.72M 157.36M
Johnson & Johnson JNJ:US $ 8192M 2043M
Neurocrine Biosciences NBIX:US $ 70.4M 36.4M
Pacira Pharmaceuticals PCRX:US $ 39.89M 13.68M
Pain Therapeutics PTIE:US $ -5.13M 1.6M
Pfizer PFE:US $ 7593M 610M
Redhill Biopharma RDHL:US $ -22.59M 6.76M
Revance Therapeutics RVNC:US $ -65.29M 0.48M
Supernus Pharmaceuticals SUPN:US $ 40.06M 20.24M
Teva Pharmaceutical Industries TEVA:US $ 1136M 34M
Vanda Pharmaceuticals VNDA:US $ 13.08M 2.02M